Economic Evaluation of Enterex® IMX, A Specialized Nutrition Supplement Containing Arginine, in the Treatment of Neurocritical Patients in México

Abstract

S105system (FAERS) database. A retrospective descriptive analysis was conducted to explore the frequency of VOD in all patients who had taken GO and Inotuzumab Ozogamicin and reported adverse event to FDA from 2000 to 2016. Our study focused mainly on reports of VOD associated with the use of either "Gemtuzuamb ozogamicin" or "Inotuzmab ozogamicin". ReSultS: A total of 200 adverse reports of VOD were retrieved from FAERS database.